MedinCell: Publication of the 2024 Financial Calendar
MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
MedinCell (Paris: MEDCL):
Event |
Date* |
Annual results 2023-2024
|
Tuesday, June 25, 2024 |
General Meeting |
Thursday, September 12, 2024 |
Half-Year results 2024-2025
|
Tuesday, December 10, 2024 |
*subject to modification. Publication after financial markets close.
About MedinCell
MedinCell is a clinical- and commercial-stage biopharmaceutical company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine already known and used active ingredients with our proprietary BEPO® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY™ (BEPO technology is licensed to Teva under the name SteadyTeq™).
We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, MedinCell currently employs more than 140 people representing more than 25 different nationalities.
UZEDY™ and SteadyTeq™ are trademarks of Teva Pharmaceuticals
View source version on businesswire.com: https://www.businesswire.com/news/home/20240201010763/en/
David Heuzé - Head of Communications
[email protected] / +33 (0)6 83 25 21 86
Media Relations
Nicolas Mérigeau
[email protected] / +33 (0)1 44 71 94 94
Investor Relations France
Louis-Victor Delouvrier/Alban Dufumier
[email protected] / +33 (0)1 44 71 94 94
Head of US Financial Strategy & IR
Grace Kim
[email protected] / +1 (646) 991-4023
Source: MedinCell
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CI Global Asset Management Announces Monthly Cash Distributions for August 2026 for Certain CI ETFs
- Bunker Hill and Silver47 Announce Merger to Create a 'Made in America' U.S. Silver & Critical Minerals Champion
- Brazil's Supreme Federal Court Issues Favorable Decision for Brazil Potash
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share